Sai Life Sciences Ltd. IPO
Sai Life Sciences Limited is launching an initial public offering (IPO) from December 11-13, 2024. The company researches, develops, and manufactures small-molecule new chemical entities, providing services to global pharmaceutical and biotech firms.
This article outlines the key details of the IPO, including issue size, price band, company financials, and important dates for investors.
This article outlines the key details of the IPO, including issue size, price band, company financials, and important dates for investors.
RI
by RA ALOK DAIYA SEBI Reg. INH000011468
About Sai Life Sciences
Founded in 1999, Sai Life Sciences Limited is a contract research, development, and manufacturing organization (CRDMO) serving 18 of the top 25 global pharmaceutical companies. The company has grown from a chemistry service provider to a full-service CRDMO supporting all stages of drug development.
Headquartered in Hyderabad, India, with offices in Boston and Manchester, the company provides integrated services from early discovery to commercial manufacturing.
Service Offerings
- CMC/CDMO capabilities including process research and commercial manufacturing
- CRO services with integrated discovery and medicinal chemistry
- Analytical services and regulatory support
- Custom synthesis and scale-up
- High-potency compound handling
- CRO services with integrated discovery and medicinal chemistry
- Analytical services and regulatory support
- Custom synthesis and scale-up
- High-potency compound handling
Infrastructure & Facilities
- State-of-the-art R&D center in Hyderabad
- FDA-approved manufacturing facilities
- Modern research laboratories
- Dedicated analytical facilities
- ISO certified quality systems
- FDA-approved manufacturing facilities
- Modern research laboratories
- Dedicated analytical facilities
- ISO certified quality systems
Team Strength & Expertise
- 3,135 total employees
- 2,353 scientific staff
- 302 Ph.D.s and 1,475 master's degree holders
- Specialized teams in medicinal chemistry and process development
- Senior management averaging 20+ years experience
- 2,353 scientific staff
- 302 Ph.D.s and 1,475 master's degree holders
- Specialized teams in medicinal chemistry and process development
- Senior management averaging 20+ years experience
With a proven track record of successful drug approvals and commercialization, Sai Life Sciences continues expanding its capabilities to serve the evolving pharmaceutical industry.
IPO Issue Details
₹3,042Cr
Total Issue Size
55,421,123 shares including fresh issue and offer for sale
₹549
Maximum Price
Price band set at ₹522-549 per share
27
Lot Size
Minimum investment ₹14,823 for retail investors
IPO Timeline
1
IPO Open Date
Wednesday, December 11, 2024
2
IPO Close Date
Friday, December 13, 2024 (UPI mandate confirmation by 5 PM)
3
Basis of Allotment
Monday, December 16, 2024
4
Initiation of Refunds
Tuesday, December 17, 2024
5
Credit of Shares to Demat
Tuesday, December 17, 2024
6
Listing Date
Wednesday, December 18, 2024
Company Financials
Note: All figures in ₹ Crore
Key highlights:
- Revenue increased by 20% between FY 2023 and FY 2024
- Profit after tax rose by 729% in the same period
- Revenue increased by 20% between FY 2023 and FY 2024
- Profit after tax rose by 729% in the same period
Key Performance Indicators
11.79%
ROE
Return on Equity as of March 31, 2024
15.96%
ROCE
Return on Capital Employed as of March 31, 2024
8.13%
RoNW
Return on Net Worth as of March 31, 2024
10.18
P/BV
Price to Book Value ratio as of March 31, 2024
Market capitalization: ₹11,418.63 Crore
PAT Margin: 5.65%
IPO Objectives and Lead Managers
Objects of the Issue:
- Repayment/prepayment in full or part, of all or certain outstanding borrowings availed by the Company
- General corporate purposes
Lead Managers:
- Kotak Mahindra Capital Company Limited
- Jefferies India Private Limited
- Morgan Stanley India Company Pvt Ltd
- Iifl Securities Ltd
Registrar: Kfin Technologies Limited
IPO Review
Key points to consider:
- The company has shown strong revenue growth and a significant increase in profitability
- It serves a global client base, including top pharmaceutical companies
- Based on FY25 annualized earnings, the issue appears aggressively priced.
- The IPO provides an opportunity to invest in an innovation-focused CRDMO in the pharmaceutical sector